[Yifan Pharmaceutical: Ryzneuta's increase in domestic production sites has been approved by the U.S. FDA] On September 30, according to Yifan Pharmaceutical news, the company's holding subsidiary Yiyi Biological Co., Ltd. received an evaluation report from the U.S. Food and Drug Administration (U.S. FDA) on the new domestic drug production site for Ryzneuta® (ibeggrastim α injection, Chinese trade name "Yilisu®") issued by the U.S. Food and Drug Administration (U.S. FDA) on September 29, 2026, local time, and approved the production of Yilisu® in China (BLA). 761134/S-007). This approval will help reduce production costs and improve supply efficiency for the supply of preparations to the United States and other markets based on the existing Sino-German supply chain. It will also help provide flexible supply according to environmental changes and improve supply chain security.